Document is current
Any future updates will be listed below
-
Authors
Al-Bzour, Noor N.
Al-Bzour, Ayah N.
Qasaymeh, Abdelrahman
Saeed, Azhar
Chen, Lujia
Saeed, Anwaar
- License Information
-
More Information
Article History
Received: 24 May 2024
Accepted: 26 November 2024
First Online: 5 December 2024
Declarations
:
: This research has not received external funding.
: Anwaar Saeed reports a leadership role with Autem therapeutics, Exelixis, KAHR medical and Bristol-Myers Squibb; consulting or advisory board role with AstraZeneca, Bristol-Myers Squibb, Merck, Exelixis, Pfizer, Xilio therapeutics, Taiho, Amgen, Autem therapeutics, KAHR medical, and Daiichi Sankyo; institutional research funding from AstraZeneca, Bristol-Myers Squibb, Merck, Clovis, Exelixis, Actuate therapeutics, Incyte Corporation, Daiichi Sankyo, Five prime therapeutics, Amgen, Innovent biologics, Dragonfly therapeutics, Oxford Biotherapeutics, Arcus therapeutics, and KAHR medical; and participation as a data safety monitoring board chair for Arcus therapeutics. The remaining authors have no relevant financial interests to disclose.
